A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations
- Authors: Tsurko VV1,2, Gromova MA2
-
Affiliations:
- ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России
- ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России
- Issue: Vol 89, No 12-2 (2017)
- Pages: 233-237
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32378
- DOI: https://doi.org/10.17116/terarkh20178912233-237
- ID: 32378
Cite item
Full Text
Abstract
The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction. Along with allopurinol, the urate-lowering drug febuxostat is first recommended in Russia. The purpose of this review is to notify physicians of the possibility of achieving the target uric acid levels when treating gout with hyperuricemia.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V V Tsurko
ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России; ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава РоссииМосква, Россия
M A Gromova
ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава РоссииМосква, Россия
References
- Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226-229.
- Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004;1:5-7.
- Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15,Suppl):S435-442.
- Choi JW, Ford ES, Gao X., Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1):109-116.
- Geiderman JM. An elderly woman with a warm, painful finger. West J Med. 2000;172(1):51-52.
- Атаханова Л.Э., Цурко В.В., Булеева И.М. Бойко И.Н., Железнов С.П., Иванова Т.Б. Подагра: от этиологии и патогенеза к диагностике и рациональной терапии. Современная ревматология. 2007;1:13-18.
- Simkin PA, Campbell PM, Larson EB. Gout in Heberden’s nodes. Arthritis Rheum. 1983;26(1):94-107.
- Воробьев П.А., Цурко В.В., Елисеева М.Е. Подагра в гериатрической практике (методические рекомендации. Часть I). Клиническая геронтология. 2016;3-4(22):3-9.
- Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014;312(24):2684-2686. https://doi.org/10.1001/jama.2014.14484
- Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826-830. https://doi.org/10.1136/annrheumdis-2012-201676
- Dalbeth N, Chen P, White M, Gamble GD, Barratt-Boyes C, Gow PJ, Orr-Walker B. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. https://doi.org/10.1136/annrheumdis-2013-203970
- Цурко В.В., Елисеева М.Е., Воробьев П.А. Особенности течения подагры в пожилом возрасте. Терапевтический архив. 2014;5(86):50-55.
- Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP, Lee JH, Hsu CC, Tsao CK, Wai JP, Chiang PH, Pan WH, Hsiung CA. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015;74(11):2034-2042. https://doi.org/10.1136/annrheumdis-2014-205312
- Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175. https://doi.org/10.1016/j.rdc.2014.01.001
- Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;64:4004-4011. https://doi.org/10.1002/art.34677
- Dalbeth N, Ames R, Gamble GD, Horne A, Wong S, Kuhn-Sherlock B, MacGibbon A, McQueen FM, Reid IR, Palmano K. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71(6):929-934. https://doi.org/10.1136/annrheumdis-2011-200156
- Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, Li HJ. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One. 2015;10(7):e0134088. https://doi.org/10.1371/journal.pone.0134088
- Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-647. https://doi.org/10.1136/annrheumdis-2014-205252
- Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
- Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068. https://doi.org/10.1002/art.27327
- van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;(9): CD010120. https://doi.org/10.1002/14651858
- Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LS, Choi YF, Yau WH, Lee KH, Graham CA. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164(7):464-4671. https://doi.org/10.7326/M14-2070
- Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226-2237. https://doi.org/10.1002/art.30389
- Wason S., Mount D., Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845-855. https://doi.org/10.1007/s40261-014-0238-6
- Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008;371(9627):1854-1860. https://doi.org/10.1016/S0140-6736(08)60799-0
- Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013;(4): CD009920. https://doi.org/10.1002/14651858.CD009920
- Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839-1848. https://doi.org/10.1136/annrheumdis-2011-200908
- Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-1384. https://doi.org/10.1002/acr.21989
- Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585-591. https://doi.org/10.1080/15257770802136032
- Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. ClinTher. 2010;32(14):2386-2397. https://doi.org/10.1016/j.clinthera.2011.01.008
- Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-414. https://doi.org/10.3109/15563650.2010.495348
- Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. https://doi.org/10.1002/art.24209
- Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
- Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-647. https://doi.org/10.1136/annrheumdis-2014-205252
- Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161-2167. https://doi.org/10.1016/S0140-6736(10)60391-1
- Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763-1771. https://doi.org/10.1016/S0140-6736(10)60391-1
- Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50(5):973-981. https://doi.org/10.1093/rheumatology/keq363
- Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2): 156-60. https://doi.org/10.1097/BOR.0b013e3283432d35
- Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82(3):141-143. https://doi.org/10.1016/j.jbspin.2015.01.002
- Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007; 166(5): 561-567.
- Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatric Psychiatry. 2006;21(4):344-348.
- Abraham A., Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014; 261(6):1133-1138. https://doi.org/10.1007/s00415-014-7331-x
- Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826-830. https://doi.org/10.1136/annrheumdis-2012-201676
- Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32.
- Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. https://doi.org/10.1002/art.24209
- Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
- Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ArthritisResTher. 2010;12(2):R63. https://doi.org/10.1186/ar2978
- Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96(1-2):90-98. https://doi.org/10.1159/000434633
- Abeles AM. Febuxostat hypersensitivity. J Rheumatol. 2012;39(3): 659. https://doi.org/10.3899/jrheum.111161
- Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957-1959. https://doi.org/10.3899/jrheum.110092
- Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314-317. https://doi.org/10.1016/j.jbspin.2015.07.011
- Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;(11): CD010457. https://doi.org/10.1002/14651858.CD010457
- Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. https://doi.org/10.1136/bmj.d8190
- Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations arereduced by fenofibrate: a systematic review and meta-analysis of randomized placebocontrolled trials. Pharmacol Res. 2015;102:63-70. https://doi.org/10.1016/j.phrs.2015.09.012
- Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157(2):255-257. https://doi.org/10.1016/j.ijcard.2012.01.092
![](/img/style/loading.gif)